A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
Status:
Not yet recruiting
Trial end date:
2023-12-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of Islatravir
(ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming
hormone therapy (GAHT) and are at low-risk for human immunodeficiency virus 1 (HIV-1)
infection.